Atrial fibrillation was associated with an increased cause-specific hazard for stroke (HR 1.88; 95% CI 1.25-2.83) in hemodialysis patients, but not when accounting for the competing risk of death.
Cohort (n=5,502)
Yes
Does atrial fibrillation increase the risk of stroke in patients with end-stage renal disease on hemodialysis when accounting for competing risks of death?
In hemodialysis patients, the high competing risk of mortality attenuates the association between atrial fibrillation and future stroke risk, highlighting the need to account for competing risks in this population.
Effect estimate: HR 1.88 (95% CI 1.25-2.83)
BACKGROUND: Stroke is common in patients with end-stage renal disease (ESRD) treated with hemodialysis (HD) and associated with high mortality rate. In the general population, atrial fibrillation (AF) is a major risk factor for stroke and therapeutic anticoagulation is associated with risk reduction, whereas in ESRD the relationship is less clear. OBJECTIVE: The purpose of this study is to demonstrate the influence of AF on stroke rates and probability in those on HD following competing risk analyses. DESIGN: A national record linkage cohort study. SETTING: All renal and stroke units in Scotland, UK. PATIENTS: All patients with ESRD receiving HD within Scotland from 2005 to 2013 (follow-up to 2015). MEASUREMENTS: Demographic, clinical, and laboratory data were linked between the Scottish Renal Registry, Scottish Stroke Care Audit, and hospital discharge data. Stroke was defined as a fatal or nonfatal event and mortality derived from national records. METHODS: Associations for stroke were determined using competing risk models: the cause-specific hazards model and the Fine and Gray subdistribution hazards model accounting for the competing risk of death in models of all stroke, ischemic stroke, and first-ever stroke. RESULTS: Of 5502 patients treated with HD with 12 348.6-year follow-up, 363 (6.6%) experienced stroke. The stroke incidence rate was 26.7 per 1000 patient-years. Multivariable regression on the cause-specific hazard for stroke demonstrated age, hazard ratio (HR) (95% confidence interval CI) = 1.04 (1.03-1.05); AF, HR (95% CI) = 1.88 (1.25-2.83); prior stroke, HR (95% CI) = 2.29 (1.48-3.54), and diabetes, HR (95% CI) = 1.92 (1.45-2.53); serum phosphate, HR (95% CI) = 2.15 (1.56-2.99); lower body weight, HR (95% CI) = 0.99 (0.98-1.00); lower hemoglobin, HR (95% CI) = 0.88 (0.77-0.99); and systolic blood pressure (BP), HR (95% CI) = 1.01 (1.00-1.02), to be associated with an increased stroke rate. In contrast, the subdistribution HRs obtained following Fine and Gray regression demonstrated that AF, weight, and hemoglobin were not associated with stroke risk. In both models, AF was significantly associated with nonstroke death. LIMITATIONS: Our analyses derive from retrospective data sets and thus can only describe association not causation. Data on anticoagulant use are not available. CONCLUSIONS: The incidence of stroke in HD patients is high. The competing risk of "prestroke" mortality affects the relationship between AF and risk of future stroke. Trial designs for interventions to reduce stroke risk in HD patients, such as anticoagulation for AF, should take account of competing risks affecting associations between risk factors and outcomes.
Findlay et al. (Tue,) conducted a cohort in End-stage renal disease treated with hemodialysis (n=5,502). Atrial fibrillation was evaluated on Stroke (fatal or nonfatal) (HR 1.88, 95% CI 1.25-2.83). Atrial fibrillation was associated with an increased cause-specific hazard for stroke (HR 1.88; 95% CI 1.25-2.83) in hemodialysis patients, but not when accounting for the competing risk of death.